---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-028304"
form_type: "8-K"
ticker: "LNSR"
cik: "0001320350"
company_name: "LENSAR, Inc."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:38:50.396701+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# LENSAR Q2 revenue $8.0M (+1% YoY), net loss ($6.8M); FDA OK for ALLY system

## Summary
- Net loss of ($6.8M) or ($0.67)/share vs. ($4.4M) or ($0.47)/share in Q2 2021.
- Total procedure volume up 8% to 33,359; U.S. volume up 15% vs. Q2 2021.
- Selling, general & administrative expenses rose 37% to $7.6M; R&D up 28% to $3.8M.
- Adjusted EBITDA (ex stock comp) was ($4.3M) vs. ($2.3M) a year ago.
- FDA cleared ALLY Adaptive Cataract Treatment System in June; expects ~10 U.S. placements in 2022.

## SEC filing metadata
- accession: 0001564590-22-028304
- form_type: 8-K
- ticker: LNSR
- cik: 0001320350
- company_name: LENSAR, Inc.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1320350/000156459022028304/0001564590-22-028304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1320350/000156459022028304/lnsr-8k_20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-028304
- JSON: https://secwatch.observer/filing/0001564590-22-028304.json
- Plain text: https://secwatch.observer/filing/0001564590-22-028304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.